Lisanti Capital Growth LLC Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Lisanti Capital Growth LLC acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 57,670 shares of the medical equipment provider's stock, valued at approximately $5,629,000. Lantheus accounts for 1.7% of Lisanti Capital Growth LLC's investment portfolio, making the stock its 12th largest holding. Lisanti Capital Growth LLC owned approximately 0.08% of Lantheus as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in LNTH. Summit Securities Group LLC purchased a new position in Lantheus in the fourth quarter valued at about $37,000. Parkside Financial Bank & Trust increased its stake in Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after purchasing an additional 280 shares in the last quarter. UMB Bank n.a. increased its stake in Lantheus by 68.2% in the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after purchasing an additional 381 shares in the last quarter. Blue Trust Inc. raised its holdings in Lantheus by 117.7% during the first quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock worth $114,000 after purchasing an additional 633 shares during the last quarter. Finally, 1620 Investment Advisors Inc. purchased a new stake in Lantheus during the fourth quarter worth $125,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 2.00% of the company's stock.

Lantheus Trading Down 3.0%

NASDAQ LNTH traded down $2.44 during mid-day trading on Tuesday, reaching $79.42. 931,757 shares of the stock were exchanged, compared to its average volume of 1,018,319. The stock has a market capitalization of $5.50 billion, a PE ratio of 22.56 and a beta of 0.12. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74. Lantheus Holdings, Inc. has a 1-year low of $73.11 and a 1-year high of $126.89. The business's fifty day simple moving average is $83.94 and its 200 day simple moving average is $90.51.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. During the same period in the prior year, the company earned $1.69 EPS. The company's revenue for the quarter was up .8% compared to the same quarter last year. On average, research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on LNTH shares. Truist Financial dropped their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. B. Riley dropped their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. Finally, Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Lantheus currently has an average rating of "Buy" and a consensus price target of $130.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.